These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

404 related articles for article (PubMed ID: 31239074)

  • 21. Trends of genetic screening in patients with pheochromocytoma and paraganglioma: 15-year experience in a high-volume tertiary referral center.
    Asban A; Kluijfhout WP; Drake FT; Beninato T; Wang E; Chomsky-Higgins K; Shen WT; Gosnell JE; Suh I; Duh QY
    J Surg Oncol; 2018 May; 117(6):1217-1222. PubMed ID: 29315604
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Metastatic sympathetic paraganglioma in a patient with loss of the SDHC gene.
    Rich T; Jackson M; Roman-Gonzalez A; Shah K; Cote GJ; Jimenez C
    Fam Cancer; 2015 Dec; 14(4):615-9. PubMed ID: 26162468
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A Guide to Pheochromocytomas and Paragangliomas.
    Guilmette J; Sadow PM
    Surg Pathol Clin; 2019 Dec; 12(4):951-965. PubMed ID: 31672301
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of pheochromocytomas and abdominal and pelvic paragangliomas with head and neck paragangliomas.
    Al-Harthy M; Al-Harthy S; Al-Otieschan A; Velagapudi S; Alzahrani AS
    Endocr Pract; 2009 Apr; 15(3):194-202. PubMed ID: 19364686
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Semiquantitative 123I-Metaiodobenzylguanidine Scintigraphy to Distinguish Pheochromocytoma and Paraganglioma from Physiologic Adrenal Uptake and Its Correlation with Genotype-Dependent Expression of Catecholamine Transporters.
    van Berkel A; Rao JU; Lenders JW; Pellegata NS; Kusters B; Piscaer I; Hermus AR; Plantinga TS; Langenhuijsen JF; Vriens D; Janssen MJ; Gotthardt M; Timmers HJ
    J Nucl Med; 2015 Jun; 56(6):839-46. PubMed ID: 25883126
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Succinate dehydrogenase B gene mutations predict survival in patients with malignant pheochromocytomas or paragangliomas.
    Amar L; Baudin E; Burnichon N; Peyrard S; Silvera S; Bertherat J; Bertagna X; Schlumberger M; Jeunemaitre X; Gimenez-Roqueplo AP; Plouin PF
    J Clin Endocrinol Metab; 2007 Oct; 92(10):3822-8. PubMed ID: 17652212
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Paraganglioma: not just an extra-adrenal pheochromocytoma.
    Laird AM; Gauger PG; Doherty GM; Miller BS
    Langenbecks Arch Surg; 2012 Feb; 397(2):247-53. PubMed ID: 22086065
    [TBL] [Abstract][Full Text] [Related]  

  • 28. New Perspectives on Pheochromocytoma and Paraganglioma: Toward a Molecular Classification.
    Crona J; Taïeb D; Pacak K
    Endocr Rev; 2017 Dec; 38(6):489-515. PubMed ID: 28938417
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Management and outcome of metastatic pheochromocytomas/paragangliomas: a monocentric experience.
    De Filpo G; Cantini G; Rastrelli G; Vannini G; Ercolino T; Luconi M; Mannelli M; Maggi M; Canu L
    J Endocrinol Invest; 2022 Jan; 45(1):149-157. PubMed ID: 34227051
    [TBL] [Abstract][Full Text] [Related]  

  • 30. PCSK2 expression in neuroendocrine tumors points to a midgut, pulmonary, or pheochromocytoma-paraganglioma origin.
    Remes SM; Leijon H; Vesterinen T; Louhimo J; Pulkkinen V; Ezer S; Kere J; Haglund C; Arola J
    APMIS; 2020 Nov; 128(11):563-572. PubMed ID: 32794589
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Over-diagnosis of potential malignant behavior in MEN 2A-associated pheochromocytomas using the PASS and GAPP algorithms.
    Stenman A; Zedenius J; Juhlin CC
    Langenbecks Arch Surg; 2018 Sep; 403(6):785-790. PubMed ID: 29779047
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical manifestations of familial paraganglioma and phaeochromocytomas in succinate dehydrogenase B (SDH-B) gene mutation carriers.
    Srirangalingam U; Walker L; Khoo B; MacDonald F; Gardner D; Wilkin TJ; Skelly RH; George E; Spooner D; Monson JP; Grossman AB; Akker SA; Pollard PJ; Plowman N; Avril N; Berney DM; Burrin JM; Reznek RH; Kumar VK; Maher ER; Chew SL
    Clin Endocrinol (Oxf); 2008 Oct; 69(4):587-96. PubMed ID: 18419787
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The clinical presentation (symptoms and signs) of sporadic and familial chromaffin cell tumours (phaeochromocytomas and paragangliomas).
    Kaltsas GA; Papadogias D; Grossman AB
    Front Horm Res; 2004; 31():61-75. PubMed ID: 14674305
    [No Abstract]   [Full Text] [Related]  

  • 34. Validation and Evaluation of 5 Scoring Systems for Predicting Metastatic Risk in Pheochromocytoma and Paraganglioma.
    Li Q; Lan Z; Jiang Y; Wang R; Li Z; Jiang X
    Am J Surg Pathol; 2024 Jul; 48(7):855-865. PubMed ID: 38712603
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The activating TERT promoter mutation C228T is recurrent in subsets of adrenal tumors.
    Liu T; Brown TC; Juhlin CC; Andreasson A; Wang N; Bäckdahl M; Healy JM; Prasad ML; Korah R; Carling T; Xu D; Larsson C
    Endocr Relat Cancer; 2014 Jun; 21(3):427-34. PubMed ID: 24803525
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Emerging molecular markers of metastatic pheochromocytomas and paragangliomas.
    Goncalves J; Lussey-Lepoutre C; Favier J; Gimenez-Roqueplo AP; Castro-Vega LJ
    Ann Endocrinol (Paris); 2019 Jun; 80(3):159-162. PubMed ID: 31053249
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prognostic indicators of malignancy in adrenal pheochromocytomas: clinical, histopathologic, and cell cycle/apoptosis gene expression analysis.
    Strong VE; Kennedy T; Al-Ahmadie H; Tang L; Coleman J; Fong Y; Brennan M; Ghossein RA
    Surgery; 2008 Jun; 143(6):759-68. PubMed ID: 18549892
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Malignancy in Pheochromocytoma or Paraganglioma: Integrative Analysis of 176 Cases in TCGA.
    Suh YJ; Choe JY; Park HJ
    Endocr Pathol; 2017 Jun; 28(2):159-164. PubMed ID: 28386672
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Correlation of the genotype of paragangliomas and pheochromocytomas with their metabolic phenotype on 3,4-dihydroxy-6-18F-fluoro-L-phenylalanin PET.
    Rischke HC; Benz MR; Wild D; Mix M; Dumont RA; Campbell D; Seufert J; Wiech T; Rössler J; Weber WA; Neumann HP
    J Nucl Med; 2012 Sep; 53(9):1352-8. PubMed ID: 22836345
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Frequent EPAS1/HIF2α exons 9 and 12 mutations in non-familial pheochromocytoma.
    Welander J; Andreasson A; Brauckhoff M; Bäckdahl M; Larsson C; Gimm O; Söderkvist P
    Endocr Relat Cancer; 2014 Jun; 21(3):495-504. PubMed ID: 24741025
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.